13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

45 trials found

diseases per page:

Showing 1 to 10 of 45 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05090371 (ClinicalTrials.gov)	March 2, 2022	12/10/2021	A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (Nf ...	A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerab ...	Relapsing-Remitting Multiple Sclerosis	Drug: Ofatumumab;Drug: Disease modifying treatment (DMT)	Novartis Pharmaceuticals	NULL	Recruiting	18 Years	50 Years	All	150	Phase 4	United States;Canada
2	EUCTR2020-004505-32-IT (EUCTR)	24/09/2021	12/10/2021	Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - ...	An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Asses ...	Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multiple sclero ...	Trade Name: COPAXONE - 20 MG/ML SOLUZIONE INIETTABILE 28 SIRINGHE PRERIEMPITE Product Name: COPAXONE Pr ...	NOVARTIS PHARMA AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	236	Phase 3	France;Spain;Germany;Italy
3	NCT04956744 (ClinicalTrials.gov)	August 31, 2021	22/6/2021	A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Mu ...	A Phase 1, Dose-Escalating, Open-label Study to Evaluate the Safety, Tolerability, and Exploratory E ...	Multiple Sclerosis	Biological: IMS001	ImStem Biotechnology	Rho, Inc.	Recruiting	18 Years	65 Years	All	30	Phase 1	United States
4	NCT04788615 (ClinicalTrials.gov)	July 23, 2021	8/3/2021	Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Lin ...	Open-Label Rater-Blind Randomized Multi-Center Parallel-Arm Active- Comparator Study to Assess the E ...	Multiple Sclerosis	Drug: Ofatumumab;Drug: First line DMT	Novartis Pharmaceuticals	NULL	Recruiting	18 Years	55 Years	All	236	Phase 3	France;Germany;Italy;Spain;United Kingdom
5	EUCTR2020-004505-32-DE (EUCTR)	06/07/2021	25/05/2021	Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - ...	An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Asses ...	Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multiple sclero ...	Trade Name: Kesimpta Product Name: ofatumumab Product Code: OMB157 INN or Proposed INN: OFATUMUMAB Produ ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	236	Phase 3	France;Spain;Germany;United Kingdom;Italy
6	EUCTR2020-004505-32-FR (EUCTR)	09/06/2021	26/04/2021	Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - ...	An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Asses ...	Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multiple sclero ...	Trade Name: Kesimpta Product Name: ofatumumab Product Code: OMB157 INN or Proposed INN: OFATUMUMAB Produ ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	236	Phase 3	France;Germany
7	NCT04792567 (ClinicalTrials.gov)	April 19, 2021	8/3/2021	Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive M ...	An Open-label Multicenter Study to Assess Response to SARS-CoV-2 modRNA Vaccines in Participants Wit ...	Secondary Progressive Multiple Sclerosis	Drug: BAF312;Drug: Baseline disease modifying therapies (DMTs)	Novartis Pharmaceuticals	NULL	Completed	18 Years	100 Years	All	41	Phase 4	Germany
8	NCT04260711 (ClinicalTrials.gov)	July 1, 2020	21/1/2020	Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).	The Safety and Cost-effectiveness of Discontinuing Disease-modifying Therapies in Stable Relapsing - ...	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive ...	Drug: DMT	VU University Medical Center	NULL	Recruiting	18 Years	N/A	All	130	N/A	Netherlands
9	EUCTR2017-001224-22-IT (EUCTR)	24/09/2019	20/01/2021	Efficacy and Safety of BIIB033 as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsi ...	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multipl ...	Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10067063;Term: Progressive rel ...	Trade Name: N/A Product Name: Opicinumab Product Code: [BIIB033] INN or Proposed INN: Opicinumab	BIOGEN IDEC RESEARCH LIMITED	NULL	Not Recruiting			Female: yes Male: yes	240	Phase 2	Sweden;United States;Czechia;Spain;Israel;United Kingdom;Switzerland;Italy;France;Hungary;Czech Repu ...
10	NCT03653273 (ClinicalTrials.gov)	January 24, 2019	28/8/2018	Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients ...	Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients ...	Multiple Sclerosis	Other: DMT withdrawal;Drug: DMT continuation	Rennes University Hospital	NULL	Recruiting	50 Years	N/A	All	250	Phase 3	France

First Previous1 2 3 4 5Next Last